However, the treatment of mubritinib for ERBB2 alone could prove advantageous for EAC, as more genomic alterations are prevalent for ERBB2 in EAC (23% EAC vs. 3% ESCC) (Wang et al., 2015). This evidence concerns the gene ERBB2 and esophageal squamous cell carcinoma.